The Effects of Ankaferd Blood Stopper

Last updated: May 28, 2023
Sponsor: Bursa Uludag Universitesi
Overall Status: Active - Enrolling

Phase

N/A

Condition

Mucositis

Canker Sores

Colon Cancer

Treatment

Ankaferd Blood Stopper

Bicarbonate

Clinical Study ID

NCT05438771
Bursa Uludag University
  • Ages 18-75
  • All Genders

Study Summary

The purpose of oral care is to reduce the effect of oral pathological microbial flora and to prevent infection, pain, and bleeding associated with cancer treatment. New agents are introduced each day to be used in the prevention and treatment of mucositis in cancer treatment. One of those agents is the Ankaferd Hemostat. Ankaferd Hemostat has pleiotropic effects and anti-infective characteristics in tissue healing. The aim of this study is to evaluate the effectiveness of the Ankaferd Hemostat in the prevention of oral mucositis due to chemotherapy in adult patients diagnosed with colorectal cancer.

The study was designed as a randomized controlled experimental study to be conducted with patients who are recently diagnosed with colorectal cancer and will receive the first course of chemotherapyd. The data were collected using the Performance Score and the Oral Mucositis Evaluation Scale.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • between the ages of 18-75
  • At least primary school graduate
  • No communication problems
  • No mouth sores/mucositis (Mucositis stage=0)
  • Having been diagnosed with colorectal cancer
  • To receive Folfox (5-Fluorouracil, oxalplatin, folinic acid) combination therapy asfirst-line therapy Not having received chemotherapy or radiotherapy with any otherdiagnosis before
  • Agreeing to participate in the study
  • ECOG performance status 0-2

Exclusion

Exclusion Criteria: Don't be a denture

  • Having an oral herpes simplex lesion
  • Smoking
  • Using Glutemine Research
  • Receiving G-CSF support
  • Having a physical disability that prevents them from using the right brushingtechnique

Study Design

Total Participants: 66
Treatment Group(s): 2
Primary Treatment: Ankaferd Blood Stopper
Phase:
Study Start date:
June 01, 2021
Estimated Completion Date:
June 02, 2023

Study Description

In patients with colorectal cancer, it is important to perform symptom management dynamically as well as specific treatments for cancer. It is extremely important for healthcare professionals to know the approaches that can be recommended to patients in the management of treatment and disease-related symptoms, in order to prevent problems that may develop in patients due to the severity of symptoms. Controlling the symptoms will increase the patient's functional capacity and quality of life.

Oral mucositis is one of the common toxic effects of chemotherapy. Pain due to mucositis causes anorexia-dysphagia development and malnutrition. As a result, systemic infections can develop, dose reduction in chemotherapy courses, increase in cost and prolongation of hospital stay. Looking at the literature, chloroxidine, glutamine, palifermin was used to prevent the development of mucositis during 5-Fu-based therapy for colon cancer. Solutions such as bicarbonate were used. Although it was determined in these studies to prevent the development of oral mucositis, the incidence of mucositis is still high. Therefore, the search for new treatments and applications to prevent mucositis continues. Ankaferd Hemostat is a herbal product used as a hemostatic agent in traditional Turkish medicine. Ankaferd Hemostat affects endothelium, blood cells, angiogenesis, cellular reproduction and vascular dynamics and stimulates mediators that lead to rapidly progressive wound healing. In addition to these, the anti-inflammatory, antimicrobial, antifungal and antioxidative effects of Ankaferd Hemostat are mentioned in the literature. In order to determine the effectiveness of Ankaferd Hemostat application in chemotherapy-induced oral mucositis in adult patients, there is a single study conducted on 20 patients with mucositis grade 2-3 with hematological malignancy. While it is stated in the literature that the healing time of mucositis is the week after 7-14 days, it was seen that this decreased to 6.6 (3-10) days in the study conducted by Atay.

In another study conducted in the field of dentistry, the effectiveness of Ankaferd Hemostat in preventing the development of oroantral fistula was evaluated. In a study comparing the use of Platelet Rich Plasma (PRP) in one arm and Ankaferd Hemostat in the other arm, it was found that the antibacterial effect was more prominent in the Ankaferd Hemostat arm and the results of edema, bleeding and infection were similar in both arms .

Connect with a study center

  • Bursa Uludag University

    Bursa, 16100
    Turkey

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.